【24h】

Evaluation of Verigene Gram-positive blood culture assay performance for bacteremic patients

机译:Verigene革兰氏阳性血液培养法对细菌性患者的评估

获取原文
获取原文并翻译 | 示例
       

摘要

The Verigene Gram-Positive Blood Culture (BC-GP) Assay (Nanosphere Inc., Northbrook, IL) is a microarray-based test designed to rapidly identify directly from positive blood cultures multiple bacterial species and their antimicrobial resistance markers. Nonduplicate blood cultures from 118 patients admitted to Erasme Hospital were prospectively enrolled. All but six organisms were members of the panel (95.6 %). For the identification of pathogens and detection of the mecA gene, the agreement with routine methods was 87.6 % and 97.7 %, respectively. The performance of the BC-GP assay was lower with polymicrobial than with monomicrobial blood cultures. Another concern of the BC-GP assay was the misidentification of Streptococcus mitis as S. pneumoniae (3/8). The BC-GP assay is a rapid and accurate tool for the simultaneous detection of multiple sepsis-causing bacteria and resistant genes from blood cultures, which could have an impact on patient management and healthcare cost.
机译:Verigene革兰氏阳性血培养(BC-GP)分析(Nanosphere Inc.,诺斯布鲁克,伊利诺伊州)是一项基于微阵列的测试,旨在直接从阳性血培养物中快速鉴定多种细菌种类及其抗微生物标记。前瞻性纳入了来自伊拉斯梅医院的118例患者的非重复血液培养。除六个生物外,所有生物均为专家组成员(95.6%)。为了鉴定病原体和检测mecA基因,与常规方法的一致性分别为87.6%和97.7%。与单微生物血液培养相比,多微生物的BC-GP分析性能较低。 BC-GP测定法的另一个问题是将链球菌性微生物误认为是肺炎链球菌(3/8)。 BC-GP测定法是一种快速准确的工具,可用于同时检测血液培养物中多种引起败血症的细菌和耐药基因,这可能会影响患者管理和医疗保健成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号